You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDarifenacin
Accession NumberDB00496  (APRD00903)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDarifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
Structure
Thumb
Synonyms
(S)-1-(2-(2,3-dihydro-5-Benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
Darifenacin
Darifenacina
Darifénacine
Darifenacinum
External Identifiers
  • UK 88525
  • UK 88525-04
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Darifenacintablet, extended release7.5 mg/1oralActavis Pharma, Inc.2016-03-15Not applicableUs
Darifenacintablet, extended release15 mg/1oralActavis Pharma, Inc.2016-03-15Not applicableUs
Enablextablet (extended-release)7.5 mgoralMerus Labs Luxco S. A R.L.2006-04-06Not applicableCanada
Enablextablet, extended release7.5 mg/1oralWarner Chilcott (US), LLC2004-12-22Not applicableUs
Enablextablet, extended release7.5 mg/1oralPhysicians Total Care, Inc.2006-11-06Not applicableUs
Enablextablet (extended-release)15 mgoralMerus Labs Luxco S. A R.L.2006-04-06Not applicableCanada
Enablextablet, extended release15 mg/1oralWarner Chilcott (US), LLC2004-12-22Not applicableUs
Enablextablet, extended release15 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-05Not applicableUs
Enablextablet, extended release15 mg/1oralPhysicians Total Care, Inc.2005-07-20Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-darifenacintablet (extended-release)15 mgoralApotex IncNot applicableNot applicableCanada
Apo-darifenacintablet (extended-release)7.5 mgoralApotex IncNot applicableNot applicableCanada
Darifenacin Hydrobromide Extended-releasetablet, extended release7.5 mg/1oralPar Pharmaceutical2016-03-15Not applicableUs
Darifenacin Hydrobromide Extended-releasetablet, extended release15 mg/1oralPar Pharmaceutical2016-03-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EmselexNovartis
XelenaDr. Reddy's
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Darifenacin Hydrobromide
ThumbNot applicableDBSALT001041
Categories
UNIIAPG9819VLM
CAS number133099-04-4
WeightAverage: 426.55
Monoisotopic: 426.230728214
Chemical FormulaC28H30N2O2
InChI KeyInChIKey=HXGBXQDTNZMWGS-RUZDIDTESA-N
InChI
InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
IUPAC Name
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
SMILES
NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylacetamide
  • Phenylpropylamine
  • Phenethylamine
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
PharmacodynamicsDarifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.
Mechanism of actionDarifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.
Related Articles
AbsorptionThe mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
Volume of distribution
  • 163 L
Protein bindingDarifenacin is approximately 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).
Metabolism

Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.

Route of eliminationNot Available
Half lifeThe elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.
Clearance
  • 40 L/h [extensive metabolizers]
  • 32 L/h [poor metabolizers]
ToxicityOverdosage can potentially result in severe central anticholinergic effects.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9989
Caco-2 permeable-0.5256
P-glycoprotein substrateSubstrate0.6385
P-glycoprotein inhibitor INon-inhibitor0.6329
P-glycoprotein inhibitor IIInhibitor0.5374
Renal organic cation transporterInhibitor0.6441
CYP450 2C9 substrateNon-substrate0.8774
CYP450 2D6 substrateNon-substrate0.5946
CYP450 3A4 substrateSubstrate0.6046
CYP450 1A2 substrateNon-inhibitor0.696
CYP450 2C9 inhibitorNon-inhibitor0.8253
CYP450 2D6 inhibitorInhibitor0.5816
CYP450 2C19 inhibitorInhibitor0.5399
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6168
Ames testNon AMES toxic0.7145
CarcinogenicityNon-carcinogens0.8847
BiodegradationNot ready biodegradable0.9599
Rat acute toxicity3.0008 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.907
hERG inhibition (predictor II)Inhibitor0.6703
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tablet (extended-release)oral15 mg
Tablet (extended-release)oral7.5 mg
Tablet, extended releaseoral15 mg/1
Tablet, extended releaseoral7.5 mg/1
Prices
Unit descriptionCostUnit
Enablex 15 mg 24 Hour tablet5.22USD tablet
Enablex 7.5 mg 24 Hour tablet5.22USD tablet
Enablex 15 mg tablet5.02USD tablet
Enablex 7.5 mg tablet5.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2230314 No2003-06-242016-08-21Canada
CA2469702 No2010-07-062022-03-05Canada
US5096890 No1995-03-132015-03-13Us
US6106864 No1996-08-212016-08-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000298 mg/mLALOGPS
logP4.35ALOGPS
logP4.54ChemAxon
logS-6.2ALOGPS
pKa (Strongest Acidic)16.21ChemAxon
pKa (Strongest Basic)10.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.56 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity128.37 m3·mol-1ChemAxon
Polarizability48.54 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Valeriano Merli, Augusto Canavesi, Paola Daverio, “Processes for preparing darifenacin hydrobromide.” U.S. Patent US20070197631, issued August 23, 2007.

US20070197631
General ReferencesNot Available
External Links
ATC CodesG04BD10
AHFS Codes
  • 86:12.00
PDB EntriesNot Available
FDA labelDownload (394 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Darifenacin.
AbirateroneThe metabolism of Darifenacin can be decreased when combined with Abiraterone.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Darifenacin.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Darifenacin.
AclidiniumAclidinium may increase the anticholinergic activities of Darifenacin.
AclidiniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Aclidinium.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Darifenacin.
AlfentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Alfentanil.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Darifenacin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Darifenacin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Alphacetylmethadol.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Darifenacin.
AmbenoniumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Ambenonium.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Darifenacin.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Darifenacin.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Darifenacin.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Darifenacin.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Darifenacin.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Darifenacin.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Darifenacin.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Anisotropine Methylbromide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Darifenacin.
AprepitantThe serum concentration of Darifenacin can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Darifenacin.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Darifenacin.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.
ArtemetherThe metabolism of Artemether can be decreased when combined with Darifenacin.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Darifenacin.
AtazanavirThe metabolism of Darifenacin can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Darifenacin can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate.
AtropineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atropine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Darifenacin.
BenactyzineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Darifenacin.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Darifenacin.
BepridilThe metabolism of Bepridil can be decreased when combined with Darifenacin.
BetaxololThe metabolism of Darifenacin can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Darifenacin can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Darifenacin is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Darifenacin.
BoceprevirThe metabolism of Darifenacin can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Darifenacin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Darifenacin can be decreased when it is combined with Bosentan.
Botulinum Toxin Type ADarifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BDarifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Darifenacin.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Darifenacin.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Darifenacin.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Darifenacin.
BuprenorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Darifenacin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Darifenacin.
ButorphanolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol.
CaffeineThe metabolism of Caffeine can be decreased when combined with Darifenacin.
CaptoprilThe metabolism of Captopril can be decreased when combined with Darifenacin.
CarbamazepineThe metabolism of Darifenacin can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Carfentanil.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Darifenacin.
CarteololThe metabolism of Carteolol can be decreased when combined with Darifenacin.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Darifenacin.
CelecoxibThe metabolism of Darifenacin can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Darifenacin.
CeritinibThe serum concentration of Darifenacin can be increased when it is combined with Ceritinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Darifenacin.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Darifenacin.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Darifenacin.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Darifenacin.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Chlorphenoxamine.
ChlorpromazineThe metabolism of Darifenacin can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Darifenacin.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Darifenacin.
CholecalciferolThe metabolism of Darifenacin can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Darifenacin.
CimetidineThe metabolism of Darifenacin can be decreased when combined with Cimetidine.
CimetropiumDarifenacin may increase the anticholinergic activities of Cimetropium.
CinacalcetThe metabolism of Darifenacin can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Darifenacin.
CitalopramThe metabolism of Darifenacin can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Darifenacin can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Darifenacin can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Darifenacin.
ClobazamThe metabolism of Darifenacin can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Darifenacin.
ClonidineThe metabolism of Clonidine can be decreased when combined with Darifenacin.
ClotrimazoleThe metabolism of Darifenacin can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Darifenacin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Darifenacin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Darifenacin can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Darifenacin.
ConivaptanThe serum concentration of Darifenacin can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Coumaphos.
CrizotinibThe metabolism of Darifenacin can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.
CyclopentolateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Cyclopentolate.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Darifenacin.
CyclosporineThe metabolism of Darifenacin can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Darifenacin can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Darifenacin.
DasatinibThe serum concentration of Darifenacin can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Darifenacin.
DecamethoniumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Decamethonium.
DeferasiroxThe serum concentration of Darifenacin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Darifenacin can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Demecarium.
DesipramineThe metabolism of Desipramine can be decreased when combined with Darifenacin.
DesloratadineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine.
DexamethasoneThe serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dexetimide.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Darifenacin.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Darifenacin.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Darifenacin.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Darifenacin.
DextromoramideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Darifenacin can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine.
DiltiazemThe metabolism of Darifenacin can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Darifenacin.
DiphenoxylateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Diphenoxylate.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Darifenacin.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Darifenacin.
DonepezilThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Donepezil.
DonepezilThe metabolism of Donepezil can be decreased when combined with Darifenacin.
DopamineThe metabolism of Dopamine can be decreased when combined with Darifenacin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Darifenacin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Darifenacin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Darifenacin.
DoxycyclineThe metabolism of Darifenacin can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Darifenacin is combined with DPDPE.
DronabinolDarifenacin may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Darifenacin can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Darifenacin can be decreased when combined with Duloxetine.
EchothiophateThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of Darifenacin can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Darifenacin.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Darifenacin.
EluxadolineDarifenacin may increase the constipating activities of Eluxadoline.
EncainideThe metabolism of Encainide can be decreased when combined with Darifenacin.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Darifenacin.
EnzalutamideThe serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Darifenacin.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Darifenacin.
ErythromycinThe metabolism of Darifenacin can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Darifenacin.
Eslicarbazepine acetateThe serum concentration of Darifenacin can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Darifenacin.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Darifenacin.
EthylmorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Ethylmorphine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Darifenacin.
EtorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Etorphine.
EtravirineThe serum concentration of Darifenacin can be decreased when it is combined with Etravirine.
FentanylThe risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl.
FenthionThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Fenthion.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Darifenacin.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Darifenacin.
FlecainideThe metabolism of Flecainide can be decreased when combined with Darifenacin.
FluconazoleThe metabolism of Darifenacin can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Darifenacin.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Darifenacin.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Darifenacin.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Darifenacin.
FluvoxamineThe metabolism of Darifenacin can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Darifenacin.
FosamprenavirThe metabolism of Darifenacin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Darifenacin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Darifenacin can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Darifenacin can be increased when it is combined with Fusidic Acid.
GalantamineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Darifenacin.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Darifenacin.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Darifenacin.
Ginkgo bilobaThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Darifenacin.
GlycopyrroniumDarifenacin may increase the anticholinergic activities of Glycopyrronium.
GranisetronThe metabolism of Granisetron can be decreased when combined with Darifenacin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Darifenacin.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Darifenacin.
HalothaneThe metabolism of Halothane can be decreased when combined with Darifenacin.
HeroinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin.
HydrocodoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Darifenacin.
HydromorphoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Darifenacin.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Darifenacin.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Darifenacin.
IdelalisibThe serum concentration of Darifenacin can be increased when it is combined with Idelalisib.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Darifenacin.
ImatinibThe metabolism of Darifenacin can be decreased when combined with Imatinib.
ImipramineThe metabolism of Darifenacin can be decreased when combined with Imipramine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Darifenacin.
IndinavirThe metabolism of Darifenacin can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.
IsavuconazoniumThe metabolism of Darifenacin can be decreased when combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Isoflurophate.
IsoniazidThe metabolism of Darifenacin can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Darifenacin can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Darifenacin.
ItraconazoleThe metabolism of Darifenacin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Darifenacin can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Darifenacin.
KetobemidoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Ketobemidone.
KetoconazoleThe metabolism of Darifenacin can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Darifenacin.
LevodopaThe metabolism of Levodopa can be decreased when combined with Darifenacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levomethadyl Acetate.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Darifenacin.
LevorphanolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levorphanol.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Darifenacin.
LisurideThe metabolism of Lisuride can be decreased when combined with Darifenacin.
LofentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Lofentanil.
LomustineThe metabolism of Lomustine can be decreased when combined with Darifenacin.
LoperamideThe metabolism of Loperamide can be decreased when combined with Darifenacin.
LopinavirThe metabolism of Darifenacin can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Darifenacin.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Darifenacin.
LovastatinThe metabolism of Darifenacin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Darifenacin can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Darifenacin can be decreased when combined with Lumefantrine.
MalathionThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Malathion.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Darifenacin.
MecamylamineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.
MefloquineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Memantine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Darifenacin.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Darifenacin.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Darifenacin.
MethadoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methadone.
MethadoneThe metabolism of Darifenacin can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methadyl Acetate.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Darifenacin.
MethanthelineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methantheline.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Darifenacin.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Darifenacin.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Darifenacin.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Darifenacin.
MetixeneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Metixene.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Darifenacin.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Darifenacin.
MetoprololThe metabolism of Darifenacin can be decreased when combined with Metoprolol.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Darifenacin.
MianserinMianserin may increase the anticholinergic activities of Darifenacin.
MianserinThe metabolism of Mianserin can be decreased when combined with Darifenacin.
MifepristoneThe metabolism of Darifenacin can be decreased when combined with Mifepristone.
MinaprineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Minaprine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Darifenacin.
MirabegronThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron.
MirabegronThe metabolism of Darifenacin can be decreased when combined with Mirabegron.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Darifenacin.
MitotaneThe serum concentration of Darifenacin can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Darifenacin.
ModafinilThe serum concentration of Darifenacin can be decreased when it is combined with Modafinil.
MorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Darifenacin is combined with N-butylscopolammonium bromide.
NabiloneDarifenacin may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Darifenacin can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Darifenacin.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Darifenacin.
NefazodoneThe metabolism of Darifenacin can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Darifenacin can be decreased when combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Darifenacin can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Darifenacin.
NevirapineThe metabolism of Darifenacin can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Darifenacin.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Darifenacin.
NicotineThe metabolism of Nicotine can be decreased when combined with Darifenacin.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Darifenacin.
NilotinibThe metabolism of Darifenacin can be decreased when combined with Nilotinib.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Darifenacin.
NormethadoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Normethadone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Darifenacin.
NVA237The risk or severity of adverse effects can be increased when Darifenacin is combined with NVA237.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Darifenacin.
OlaparibThe metabolism of Darifenacin can be decreased when combined with Olaparib.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Darifenacin.
OpiumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Orphenadrine.
OsimertinibThe serum concentration of Darifenacin can be increased when it is combined with Osimertinib.
OxybutyninThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Darifenacin.
PalbociclibThe serum concentration of Darifenacin can be increased when it is combined with Palbociclib.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Darifenacin.
PancuroniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium.
PanobinostatThe metabolism of Darifenacin can be decreased when combined with Panobinostat.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Darifenacin.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Darifenacin.
Peginterferon alfa-2bThe serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Darifenacin.
PentazocineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.
PentobarbitalThe metabolism of Darifenacin can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentolinium.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Darifenacin.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Darifenacin.
PethidineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Darifenacin.
PhenforminThe metabolism of Phenformin can be decreased when combined with Darifenacin.
PhenobarbitalThe metabolism of Darifenacin can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Darifenacin can be increased when combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Physostigmine.
PindololThe metabolism of Pindolol can be decreased when combined with Darifenacin.
PipecuroniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.
PiperazineThe metabolism of Piperazine can be decreased when combined with Darifenacin.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Darifenacin.
PirenzepineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Darifenacin.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Darifenacin.
PosaconazoleThe metabolism of Darifenacin can be decreased when combined with Posaconazole.
Potassium ChlorideDarifenacin may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Darifenacin.
PrimidoneThe metabolism of Darifenacin can be increased when combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Darifenacin.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Darifenacin.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Darifenacin.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Darifenacin.
PromazineThe metabolism of Darifenacin can be decreased when combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Darifenacin.
PropafenoneThe serum concentration of Darifenacin can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Darifenacin.
PropanthelineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Propantheline.
PropofolThe metabolism of Propofol can be decreased when combined with Darifenacin.
PropranololThe metabolism of Propranolol can be decreased when combined with Darifenacin.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Darifenacin.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Darifenacin.
PyridostigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Pyridostigmine.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Darifenacin.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Darifenacin.
QuinidineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Quinidine.
QuinineThe metabolism of Darifenacin can be decreased when combined with Quinine.
RamosetronDarifenacin may increase the constipating activities of Ramosetron.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Darifenacin.
RanolazineThe metabolism of Darifenacin can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Darifenacin.
repinotanThe metabolism of repinotan can be decreased when combined with Darifenacin.
RifabutinThe metabolism of Darifenacin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Darifenacin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Darifenacin can be increased when combined with Rifapentine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Darifenacin.
RitonavirThe metabolism of Darifenacin can be decreased when combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Rivastigmine.
RolapitantThe metabolism of Darifenacin can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Darifenacin can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Darifenacin.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Darifenacin.
SaquinavirThe metabolism of Darifenacin can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.
SertindoleThe metabolism of Sertindole can be decreased when combined with Darifenacin.
SertralineThe metabolism of Sertraline can be decreased when combined with Darifenacin.
SildenafilThe metabolism of Darifenacin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Darifenacin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Darifenacin can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Darifenacin.
SolifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Solifenacin.
SparteineThe metabolism of Sparteine can be decreased when combined with Darifenacin.
St. John's WortThe serum concentration of Darifenacin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Darifenacin can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.
SulfisoxazoleThe metabolism of Darifenacin can be decreased when combined with Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.
TacrineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Tacrine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Darifenacin.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Darifenacin.
TapentadolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tapentadol.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Darifenacin.
TelaprevirThe metabolism of Darifenacin can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Darifenacin can be decreased when combined with Telithromycin.
TerbinafineThe metabolism of Darifenacin can be decreased when combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Darifenacin.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Darifenacin.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Darifenacin.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Darifenacin.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Darifenacin.
ThioridazineThe metabolism of Darifenacin can be decreased when combined with Thioridazine.
TiclopidineThe metabolism of Darifenacin can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Darifenacin.
TiotropiumDarifenacin may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Darifenacin.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Darifenacin.
TocilizumabThe serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.
TolterodineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Topiramate.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Darifenacin.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin.
TranylcypromineThe metabolism of Darifenacin can be decreased when combined with Tranylcypromine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Darifenacin.
TrichlorfonThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Darifenacin.
TrimethaphanThe risk or severity of adverse effects can be increased when Darifenacin is combined with Trimethaphan.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Darifenacin.
TropicamideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Darifenacin.
TubocurarineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Darifenacin.
UmeclidiniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.
VenlafaxineThe metabolism of Darifenacin can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Darifenacin can be decreased when combined with Verapamil.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Darifenacin.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Darifenacin.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Darifenacin.
VoriconazoleThe metabolism of Darifenacin can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Darifenacin.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Darifenacin.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Darifenacin.
ZiprasidoneThe metabolism of Darifenacin can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Darifenacin.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Bharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G215-9. doi: 10.1152/ajpgi.00072.2010. Epub 2010 Apr 15. [PubMed:20395537 ]
  2. Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. doi: 10.1016/j.phrs.2009.01.013. Epub 2009 Feb 5. [PubMed:19416629 ]
  3. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  2. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  2. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  2. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
  2. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13